Barclays Maintains Overweight on Moderna, Lowers Price Target to $155
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Moderna (NASDAQ:MRNA) but lowers the price target from $168 to $155.
August 02, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Moderna but lowers the price target from $168 to $155.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on Moderna's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100